A recent study to investigate the safety and efficacy of serotonin reuptake inhibitors suggests that these drugs are beneficial for the treatment of depressive disorders in Parkinson disease. Whether these treatments will offer such benefits in the long term compared with other pharmacological and nonpharmacological approaches remains to be determined.
References
Aarsland, D., Påhlhagen, S., Ballard, C. G., Ehrt, U. & Svenningsson, P. Depression in Parkinson disease—epidemiology, mechanisms and management. Nat. Rev. Neurol. 8, 35–47 (2012).
Schrag, A. et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov. Disord. 22, 1077–1092 (2007).
Seppi, K. et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 26 (Suppl. 3), S42–S80 (2011).
Skapinakis, P. et al. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol. 10, 49 (2010).
Bondon-Guitton, E. et al. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. Mov. Disord.. 26, 2226–2231 (2011).
Richard, I. H. et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 78, 1229–1236 (2012).
Menza, M. et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 72, 886–892 (2009).
Schulz, K. F. & Grimes, D. A. Blinding in randomised trials: hiding who got what. Lancet 359, 696–700 (2002).
Barone, P. et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 573–580 (2010).
Nandagopal, J. J. & DelBello, M. P. Selegiline transdermal system: a novel treatment option for major depressive disorder. Expert Opin. Pharmacother. 10, 1665–1673 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
O. Rascol has acted as a scientific advisor for Boehringer-Ingelheim in the development of antiparkinsonian medications. He has received unrestricted scientific grants from Novartis, Boehringer-Ingelheim, Eisai, Euthérapie, Faust Pharmaceuticlas, GlaxoSmithKline, Lundbeck, Solvay, and TEVA. S. Perez-Lloret declares no competing interests.
Rights and permissions
About this article
Cite this article
Perez-Lloret, S., Rascol, O. Serotonin reuptake inhibitors for depression in PD. Nat Rev Neurol 8, 365–366 (2012). https://doi.org/10.1038/nrneurol.2012.111
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2012.111
- Springer Nature Limited
This article is cited by
-
Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson’s disease
BMC Neuroscience (2014)
-
Methylphenidate
CNS Drugs (2013)